• nor-Binaltorphimine Dihydrochloride: Circuit-Specific Insigh

  2026-06-10

  Explore how nor-Binaltorphimine dihydrochloride, a potent κ-opioid receptor antagonist, enables precise dissection of central pain circuits and opioid tolerance. This article delivers a deeper, circuit-level analysis that informs advanced opioid receptor signaling research.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina

  2026-06-10

  This study identifies gramine as a potent inducer of ferroptosis in triple-negative breast cancer (TNBC) by modulating the CUL3–MTDH ubiquitination axis. The findings provide a mechanistic basis for exploiting ferroptosis pathways in TNBC therapy and inform future proteomic and molecular workflow design.

• NIR-Activated Co-SAE Catalysts Advance Multimodal Photothera

  2026-06-09

  This study presents a near-infrared (NIR)-triggered, cobalt single-atom enzyme (Co-SAE) system embedded in hollow N-doped carbon spheres, enabling synergistic photodynamic, photocatalytic, and photothermal therapy for head and neck cancer. The work’s mechanistic insights into ROS-driven ferroptosis and apoptosis highlight new avenues for noninvasive, function-preserving cancer treatment.

• Mitigating Pollen Interference in EEM Fluorescence for Bioae

  2026-06-09

  This study introduces a robust spectral data transformation and classification workflow to effectively remove pollen-induced interference in excitation–emission matrix (EEM) fluorescence analysis of hazardous bioaerosols. The approach significantly increases classification accuracy for pathogens and toxins, offering a methodological advance for rapid environmental monitoring.

• BX795: A Mechanistic Lever for Translational Cancer Research

  2026-06-08

  This article provides translational researchers with a mechanistic and strategic exploration of BX795, a potent PDK1 inhibitor from APExBIO. It connects PI3K/Akt/mTOR and innate immune pathways, details experimental parameters, reviews competitive approaches, and contextualizes BX795's role in in vitro cancer drug evaluation—advancing the discussion beyond standard product pages.

• YBX1-Driven SHANK3 Methylation Dynamics in Schizophrenia Eti

  2026-06-08

  This study uncovers a novel mechanism in schizophrenia, demonstrating how YBX1 regulates DNA methylation-dependent SHANK3 expression in cortical interneurons and peripheral blood mononuclear cells. These findings suggest SHANK3 promoter hypermethylation as both a neuropathological mechanism and a potential peripheral biomarker for schizophrenia.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-07

  Schwartz's dissertation addresses the limitations of traditional in vitro drug response assays by systematically dissecting how anti-cancer agents impact proliferation and cell death. The study introduces nuanced metrics and experimental strategies, offering researchers a more accurate framework for evaluating targeted therapies such as tyrosine kinase inhibitors.

• Flumequine and the Future of DNA Topoisomerase II Inhibitor

  2026-06-06

  Explore how Flumequine, a potent DNA topoisomerase II inhibitor, is redefining precision in DNA replication research. This article uniquely connects advanced in vitro drug response metrics with practical assay optimization for cancer and antibiotic resistance studies.

• RWJ 67657: Selective p38α/β MAPK Inhibitor for Inflammatory

  2026-06-05

  RWJ 67657 (also known as JNJ-3026582) is a potent, orally active inhibitor of p38α and p38β MAP kinases, providing high selectivity and efficacy in TNF-alpha suppression. With nanomolar-to-micromolar IC50 values and minimal off-target activity, it is a benchmark tool for inflammatory disease research and translational assay development.

• Biotin-Azide in Molecular Profiling: Beyond Click Chemistry

  2026-06-05

  Discover how Biotin Azide enables precision biotinylation of alkynylated biomolecules and advances molecular profiling workflows. This article explores cutting-edge applications, addresses practical protocol nuances, and links the latest mechanistic insights to real-world assay design.

• Tin Mesoporphyrin IX: Precision Heme Oxygenase Inhibition in

  2026-06-04

  Tin Mesoporphyrin IX (chloride) is a benchmark tool for inhibiting heme oxygenase in metabolic disease and antiviral workflows. This article delivers actionable protocol enhancements, troubleshooting strategies, and advanced use-case insights drawn from cutting-edge studies and APExBIO’s rigorously validated product.

• Linoleic Acid (C18:2): Technical Guidance for Lab Assays

  2026-06-04

  Linoleic Acid (C18:2(9Z,12Z)) from APExBIO serves as a precision reagent for studying membrane fluidity, oxidative stress, and essential fatty acid biology in cell-based and animal models. It is best suited for workflows requiring direct modulation of redox balance or modeling nutritional deficiency, but it is not recommended for protocols demanding long-term stock solution storage or direct aqueous solubility.

• Palonosetron Hydrochloride: 5-HT3 Antagonist in Translationa

  2026-06-03

  Palonosetron hydrochloride stands apart as a highly selective, dual-site 5-HT3 receptor antagonist optimized for both mechanistic research and translational protocols. Its unparalleled potency and unique binding kinetics empower reliable CINV/RINV modeling and advanced transporter assays.

• Ribonuclease R (RNase R) (20 U/μL): Reliable Circular RNA En

  2026-06-03

  This article addresses critical challenges in circular RNA enrichment and RNA structure-function studies by highlighting the application of Ribonuclease R (RNase R) (20 U/μL) (SKU K3061). Through scenario-driven Q&A, it delivers evidence-based guidance for biomedical researchers, showing how SKU K3061 ensures reproducibility, sensitivity, and cost-effective workflows in cell viability and inflammation assays.

• mTORC1-IRE1α Pathway Drives Palmitate-Induced Lipotoxicity i

  2026-06-02

  This study reveals that activation of the mTORC1-IRE1α pathway is central to palmitate-induced triglyceride overproduction and cell death in hepatocytes. These findings clarify mechanisms of lipotoxicity relevant to metabolic disease and highlight therapeutic targets for future intervention.

450 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page